Innovation Award of the GDCh Division of Medicinal Chemistry

Deadline: November 30, 2023

objective
Every year, the GDCh Division of Medicinal Chemistry and the DPhG Division for pharmaceutical/medicinal chemistry jointly award this prize in recognition of outstanding and independent scientific research in medicinal and pharmaceutical chemistry – evidenced by publications in scientific journals.

The price
The award comes with a certificate of award and prize money of 5,000 euros donated by the two Divisions . The prize can be shared. The award will be presented at the Frontiers in Medicinal Chemistry Conference , which will take place from March 17 to 20, 2024 in Munich. The award awardee will be invited to present their own research area in a short presentation during the Conference . The Division bears the costs of attending the conference. A prize committee, which is appointed by the two Divisions, decides on the award of the prize; each Division appoints two members.

Nomination/Application
Nominations and applications are possible. The doctorate of the candidates should not be older than ten years. Publications that appeared between 2019 and 2023 are considered. Each application/nomination contains the following information:

 

• concise justification (max. 1 page),
• CV (including contact details),
• Opinion from a mentor,
• Overview of self-employed postdoctoral activities with regard to habilitation or equivalent qualifications and
• electronic reprints of the publications.

submission
Please send your suggestion by e-mail and summarized in a PDF file to the GDCh Office for the attention of Maike Fries.

The Innovation Award 2023 was presented on April 4, 2023 at the Division conference "Frontiers in Medicinal Chemistry 2023" in Vienna
dr Matthew Schiedel   awarded "in recognition of his outstanding, original and pioneering research work. By addressing intracellular allosteric binding sites of G protein-coupled receptors, Dr. Schiedel succeeded in developing novel concepts for controlling receptor selectivity and functional selectivity. By applying PROTAC strategies GPCRs could be targeted for proteasomal degradation. The scientific success of his innovative and independent work is impressively documented by publications in internationally renowned journals."

The Innovation Award was presented to Dr. Steffen Pockes and Dr. Awarded to Oliver Thorn-Seshold.

dr Pockes: "In recognition of his outstanding, original and pioneering research work. The scientific work of Dr. Pockes deals with the development of novel active substances to combat neurodegenerative diseases. The focus is on innovative ligands for G protein-coupled receptors and selective caspase inhibitors The scientific success of his innovative and independent research work is documented by publications in the highest-ranking journals of medicinal chemistry."

dr Thorn-Seshold: "In recognition of his outstanding, original and pioneering research work. Dr. Thorn-Seshold is developing novel, structurally chemical, photoswitchable modulators of the cytoskeleton. This work ranges from basic research to application in vivo. With photoswitchable antimitotics and vascular-damaging agents, new strategies for tumor therapy. The scientific success of his innovative and independent work is documented by publications in the highest international journals and by the considerable acquisition of third-party funds."